Science & Technology
TT-036 for the treatment of scleroderma-associated pulmonary fibrosis
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41HL176277-01
Award Ceiling
$390K
Award Floor
$390K
Close Date
Sep 4, 2025
Total Funding
$390K
Expected Awards
1
Posted Date
Sep 5, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41HL176277-01
Description
STTR Phase Phase I award: "TT-036 for the treatment of scleroderma-associated pulmonary fibrosis" awarded to Thendor Therapeutics LLC in LEXINGTON, South Carolina. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $389,754. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.